Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Given Average Recommendation of “Moderate Buy” by Brokerages

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

Several brokerages recently commented on FSNUY. Citigroup began coverage on shares of Fresenius SE & Co. KGaA in a report on Tuesday, August 1st. They set a “buy” rating on the stock. HSBC downgraded shares of Fresenius SE & Co. KGaA from a “buy” rating to a “hold” rating in a report on Tuesday, September 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Fresenius SE & Co. KGaA from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th.

Fresenius SE & Co. KGaA Stock Performance

Shares of OTCMKTS:FSNUY opened at $7.52 on Tuesday. The company has a market capitalization of $16.80 billion, a price-to-earnings ratio of 68.36 and a beta of 1.09. Fresenius SE & Co. KGaA has a 12 month low of $6.07 and a 12 month high of $8.38. The firm’s 50-day moving average is $7.19 and its 200 day moving average is $7.34. The company has a current ratio of 1.20, a quick ratio of 0.89 and a debt-to-equity ratio of 0.56.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.